

Leveraging functional genomics to reveal novel targets for cancer treatment

Horizon Europe

Gerado em: 8 de outubro de 2026

● PENDENTE

Código

HORIZON-MISS-2027-02-CANCER-01

Âmbito

Internacional

Localização

Europa

Curadoria

Marlene Faria

Detalhes Financeiros

Tipo de apoio

Fundo Perdido

Taxa Máxima de Financiamento

100%

Dotação

3.2B€

Valor Elegível do Projeto

7M€ - 8M€

Datas e Prazos

Data de Publicação

Não definida

Data de Abertura

10 de fevereiro de 2027

Fase única

16 de setembro de 2027 às 17:00 GMT+2

Descrição

Objectives

This topic aims to advance the understanding of cancer initiation, progression and treatment resistance through the application of functional genomics and multi-omics approaches, contributing directly to the objectives of the EU Cancer Mission. Particular attention is given to paediatric and adolescent cancers, rare cancers, refractory cancers, cancers with limited treatment options, and tumour types with low survival rates. Projects are expected to identify and validate novel therapeutic targets, improve understanding of tumour heterogeneity and resistance mechanisms, and support the development of next-generation genomically informed cancer treatments. Applicants are encouraged to leverage advanced technologies such as single-cell analysis, spatial transcriptomics, liquid biopsies, epigenetic profiling, AI, computational modelling and precision oncology approaches.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA). The topic has an indicative budget of around €32 million, with the European Commission expecting to fund approximately four projects. The expected EU contribution is between €7 million and €8 million per project, although proposals requesting different amounts may also be considered where appropriately justified. As a Research and Innovation Action, projects are eligible for 100% funding of eligible costs in accordance with Horizon Europe rules.

Despesas Elegíveis

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

Elegibilidade

Setores Elegíveis

Saúde & Ciências da Vida

Modalidade de Candidatura

Consórcio / Copromoção

Tipologia das Empresas

- Micro
- PME
- Small Mid-Cap
- Mid-Cap
- Grande
- Entidades não empresariais do sistema de I&I (ENESII)
- Entidades privadas sem fins lucrativos
- Entidades públicas

Tipos de Ação

- Research and Innovation Actions
- Clinical Trials
- Digital Health Solutions
- Cross-Border Integration

Detalhes do Programa UE

ID da Chamada

HORIZON-MISS-2027-02-CANCER-01

Cluster

Mission

Destino

Cancer

Modo de Submissão

Single-stage

Contribuição UE

Around €7,000,000.00 to €8,000,000.00 per project

Projetos Esperados

4

Regra de Taxa de Financiamento

Up to 100% of eligible costs for Research and Innovation Actions (RIA)

Links Oficiais

Regulamento Oficial

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-01?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-MISS-2027-02-CANCER-01&isExactMatch=true&status=31094501,31094502,31094503>

Página no Grantavia

<https://grantavia.com/pt/incentives/leveraging-functional-genomics-to-reveal-novel-targets-for-cancer-treatment>

Agendar reunião

<https://calendly.com/sandra-cardoso-epsa/reuniao>